COVA 322

Drug Profile

COVA 322

Alternative Names: Bispecific anti-TNF/IL-17A FynomAb; COVA322

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Covagen
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Bispecific antibodies
  • Mechanism of Action Interleukin-17 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Plaque psoriasis
  • Preclinical Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 26 Feb 2016 Covagen terminates a phase-I/II trial in Plaque psoriasis in Germany (NCT02243787) (IV)
  • 10 Feb 2016 Phase-I/II development is ongoing in Germany
  • 25 Aug 2014 Cilag GmbH International acquires Covagen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top